{"preliminary_commentary":{"by_channel":{"x_thread":31,"podcast":9,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02784171\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"untreated advanced pleural mesothelioma","name":"IND.227","nct_id":"NCT02784171","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ind-227-nct02784171. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles","label":"Arm A - Cisplatin/Pemetrexed","type":"ACTIVE_COMPARATOR"},{"description":"Pembrolizumab 200 mg\\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles","label":"Arm B - Cisplatin/Pemetrexed/Pembrolizumab","type":"ACTIVE_COMPARATOR"},{"description":"Pembrolizumab 200 mg\\* IV 30 min Day 1 every 21 days for a total of 2 years","label":"Arm C - Pembrolizumab (Phase II only)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute, Naples","Merck Sharp & Dohme LLC","Intergroupe Francophone de Cancerologie Thoracique"],"completion_date":{"date":"2024-10-11","type":"ACTUAL"},"conditions":["Mesothelioma"],"enrollment":{"count":520,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2024-12-10","lead_sponsor":"Canadian Cancer Trials Group","official_title":"A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2024-10-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression","timeFrame":"PFS was monitored continuously, with assessments every 6 weeks for 3 visits, then every 12 weeks, 4 weeks post-discontinuation, every 12 weeks until progression, and every 24 weeks until death, over an average of 16.2 months."},{"measure":"Phase III: Overall Survival Defined as Time From Randomization to the Date of Death From Any Cause","timeFrame":"Survival was monitored continuously throughout the study and during follow-up. Patients were evaluated for each cycle, 4 weeks after discontinuation, every 12 weeks until progression, and then every 24 weeks until death, an average of 16.2 months."}],"references":[{"citation":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3.","pmid":"37931632","type":"RESULT"},{"citation":"Uprety D. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma. Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2. No abstract available.","pmid":"33358660","type":"DERIVED"}],"start_date":{"date":"2016-11-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma","url":"https://clinicaltrials.gov/study/NCT02784171"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ind-227-nct02784171"}